FindTrial
Sign In

Effect of botulinum toxin A on Raynaud's phenomenon in patients with systemic sclerosis

Effect of botulinum toxin A on Raynaud's phenomenon in patients with systemic sclerosis - BTX-A on Raynaud's phenomenon in SSc

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000017617
Enrollment
10
Registered
2015-05-19
Start date
2014-11-01
Completion date
Unknown
Last updated
2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Raynaud&#39

Interventions

Botulinum toxin A injection

Sponsors

Gunma University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria: Patients under the age 18, with the pregnancy or having the past medical histories with BTX-A were excluded.

Design outcomes

Primary

MeasureTime frame
The change in severity of RP, including the frequency, pain, color and duration, by the Raynaud score and VAS at 4 weeks after treatment compared with the baseline.—

Countries

Japan

Contacts

Public ContactSei-ichiro Motegi

Gunma University Graduate School of Medicine Department of Dermatology

smotegi@gunma-u.ac.jp027-220-8284

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026